5-Star Opportunities in Big Pharma
These well-known names are worth a look.
These well-known names are worth a look.
One of the primary debates at the Morningstar Investment Conference was over big pharma. Some managers, such as David Winters of Wintergreen Fund and Rajeev Bhaman of Oppenheimer Global (OPPAX), worried that sluggish research and development and possible government intervention limited the potential of the industry. Others, such as Diana Strandberg of Dodge & Cox Global (DODWX) and Dodge & Cox International (DODFX), thought several big pharma companies were undervalued due to overstated worries, and were attractive not only for their cheap prices, but also for their sturdy cash flows.
At Morningstar, we think there are a handful of worthy firms available at great prices, presenting solid opportunities even in light of the industry risks. We used Morningstar's Premium Stock Screener to look for 5-star stocks in the drug industry with market caps above $150 million.
Below are three of the stocks that passed. Click here to run this screen yourself here.
GlaxoSmithKline PLC (GSK)
Price: $34.09 | Fair Value Estimate: $49 | Moat: Wide | Uncertainty: Medium
From the Analyst Report:
Generics are hurting Glaxo's near-term growth, but the company is laying the foundation for improved future growth with the launch of several vaccines. The firm recently launched pneumococcal vaccine Synflorix in Europe, which we believe will develop into a blockbuster. Glaxo's other recent vaccine launches that are likely to develop into blockbusters include human papillomavirus vaccine Cervarix and rotavirus vaccine Rotarix. We expect Cervarix will launch in the United States in 2010.
Johnson & Johnson (JNJ)
Price: $56.29 | Fair Value Estimate: $80 | Moat: Wide | Uncertainty: Low
From the Analyst Report:
Johnson & Johnson stands alone as a leader across the major health-care industries. The company maintains a diverse revenue base, a robust research pipeline, and exceptional cash-flow generation that together create a wide economic moat. Patent losses on antipsychotic Risperdal and neuroscience drug Topamax, as well as recent side-effect concerns with anemia drug Procrit, will weigh on near-term performance. However, we remain confident that the company's breadth can overcome these issues.
Pfizer (PFE)
Price: $15.09 | Fair Value Estimate: $26 | Moat: Wide | Uncertainty: Medium
From the Analyst Report:
Pfizer's foundation remains solid based on strong cash flows generated from a basket of diverse drugs. The company's large size confers significant competitive advantages in developing new drugs. This unmatched heft, combined with a broad portfolio of patent-protected drugs, has helped Pfizer build a wide economic moat around its business.
Pfizer's size establishes the largest economy of scale in the pharmaceutical industry. In a business where drug development needs a lot of shots on goal to be successful, Pfizer has the financial resources and the established research power to support the development of more new drugs. We believe Pfizer will be more of a cost-reduction story versus a top-line growth company over the next several years, and the past quarter shows solid execution on cost savings.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals
and individual investors. These products and services are usually sold through
license agreements or subscriptions. Our investment management business generates
asset-based fees, which are calculated as a percentage of assets under management.
We also sell both admissions and sponsorship packages for our investment conferences
and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.